蔡修宇教授：肺癌免疫治疗耐药及临床策略

这也是未来肿瘤免疫治疗的发展方向。此外，除原有治疗手段以外，不断开发肿瘤免疫治疗的新靶点及新药物也是解决免疫耐药现状的方法之一。

本文插图
策划：GoEun ，梅浙

题图来源：站酷海洛PLUS
参考文献
1. Yang YN, Yang L, Wang Y, et al. Immunotherapy for Lung Cancer: Mechanisms of Resistance and Response Strategy. Zhongguo Fei Ai Za Zhi, 2021, 24(2): 112-123.
2. Walsh RJ, Soo RA. Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies. Ther Adv Med Oncol, 2020, 12: 1758835920937902 .
3. George S, Miao D, Demetri GD, et al. Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. Immunity, 2017, 46(2): 197-204.
4. Le DT, Durham JN, Smith K N, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 2017, 357(6349): 409-413.
5. Gettinger S, Choi J, Hastings K, et al. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung Cancer. Cancer Discov, 2017, 7(12): 1420-1435.

蔡修宇教授：肺癌免疫治疗耐药及临床策略｜肿瘤学术节( 五 )